BEIJING, June 26, 2018 /PRNewswire/ -- Ascletis BioScience Co., Ltd.("Ascletis") and CR Pharmaceutical Commercial Group Co.,Ltd. jointly announced today that the two parties signed a strategic cooperation agreement in Beijing. The two parties will work closely in distribution networks and end-user services, to prepare for the launch of GanovoŽ(danoprevir).
CR Pharmaceutical Commercial Group Co., Ltd., a subsidiary and grade-1 profit center of China Resources Pharmaceutical Group Limited (CR Pharma) (stock code: 3320.HK), is the second largest distributor in Chinese pharmaceutical market for sales and distribution services including marketing & sales, distribution and logistics, academic seminars and supply chain value added services. CR Pharmaceutical Commercial Group Co., Ltd. directly distributes products to hospitals and other medical institutions in 31 provinces in China.
"HCV is one of the major public health issues in China. We need to work closely with all parties of the China community to prevent and eliminate HCV ultimately. Meanwhile, due to the large number of the Chinese HCV patients population distributed widely in various parts of China, it can create a huge challenge to us to deliver GanovoŽ to the patients rapidly and timely." said Jinzi J. Wu, Ph.D., Ascletis' founder, President and CEO. "CR Pharmaceutical Commercial Group Co., Ltd. is a leading pharmaceutical supply chain solution provider in China. The collaboration with CR is an important strategic move for both of us to prevent and eliminate HCV. I sincerely hope that we can leverage the comparative advantages of both parties and make a unique and significant contribution to China goal to the elimination of HCV disease in China in 2030."
Mr. Li Xiangming, General Manager of CR Pharmaceutical Commercial Group Co., Ltd., said, "As a leading innovative drug company in China, Ascletis has demonstrated strong social responsibility shared by CR Pharmaceutical Commercial Group Co., Ltd. as well. We will take full advantage of our nationwide distribution network, to provide value added services in the areas of marketing and sales, distribution and logistics, and supply chain to Ascletis, in order to benefit more Chinese patients with the 1st HCV drug in innovative category ever developed by a domestic company and create more social value."
View original content:http://www.prnewswire.com/news-releases/ascletis-and-cr-pharmaceutical-commercial-group-co-ltd-signed-strategic-cooperation-agreement-300672169.html
SOURCE Ascletis BioScience Co., Ltd.
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All